Fig. 2From: Telbivudine for the treatment of chronic hepatitis B in HBeAg-positive patients in China: a health economic analysisCost-effectiveness frontier a without renal impact and b including renal impact. ADV adefovir dipivoxil, BSC best supportive care, CE cost-effectiveness, ETV entecavir, LAM lamivudine, LDT telbivudine, QALY quality-adjusted life-year, TDF tenofovirBack to article page